Indian Immunologicals Limited

02/01/2026

Indian Immunologicals Limited (IIL) a wholly owned subsidiary of the National Dairy Development Board (NDDB) congratulates Dr Meenesh C Shah, Chairman (NDDB and IIL) on his appointment for 3.5 years as Chairman of NDDB by Government of India.

His exemplary leadership in the field of dairying, sustainability and organisational excellence will continue to show way in strengthening cooperatives in the world’s largest country for dairying.

His compassion and care as Chairman of IIL and Pristine, New Zealand has guided our companies and enabled stay composed and perform exceedingly well during our difficult times.

This recognition by the Government of India to extend the services of Dr Meenesh C Shah as Chairman of NDDB will also consolidate NDDB and it’s subsidiaries in adding immense value to the nation in realising the dream of Viksit Bharat 2047.

27/12/2025

'Isolated Incident': Indian Immunologicals Limited Issues Clarification After Australia's Advisory On Counterfeit Anti-Rabies Vaccine Abhayrab

Source: The Free Press Journal | Date: December 27, 2025
Click on the article below to know more:

Indian Immunologicals Limited clarified concerns over counterfeit Abhayrab after an Australian advisory, saying reports relate to a single batch identified in January 2025. The Hyderabad-based firm called it an isolated incident, confirmed the batch is off shelves and said all vaccines are tested by...

27/12/2025

Abhayrab Controversy: Clarifying the Counterfeit Vaccine Concerns

Source: Devdiscourse | Date: December 27, 2025
Click on the article below to know more:

Indian Immunologicals Limited clarifies concerns about a counterfeit batch of its rabies vaccine, Abhayrab, following an advisory by Australia. The issue involves a specific batch from 2024, with no broader risk identified. IIL urges a review of the advisory to prevent public mistrust.

27/12/2025

Fake Rabies Vaccine Advisory Explained: What Australia Warned, What India Clarified

Source: NDTV | Date: December 27, 2025
Click on the article below to know more:

A recent Australian advisory suggested that counterfeit rabies vaccines were circulating in India. The Indian makers of Abhayrab have now rejected these claims.

27/12/2025

Over-cautionary Manufacturer on Australia's advisory against its rabies vaccine.

Source: THEWEEK | Date: December 27, 2025
Click on the article below to know more:

New Delhi, Dec 27 (PTI) Days after Australia issued an advisory against counterfeit rabies vaccine in India, a public sector

27/12/2025

Australia issues advisory on counterfeit anti-rabies vaccine in India; pharma refutes charges. Indian Immunologicals Limited says the vaccine batch is no longer in circulation.

Source: TheHindu | Date: December 27, 2025
Click on the article below to know more:

Australian government warns of counterfeit rabies vaccine in India; Indian Immunologicals clarifies the issue is resolved and batch is withdrawn.

24/12/2025

We are happy to share that Indian Immunologicals Limited (IIL) has been awarded for Innovation – Human Health Product of the Year (Havisure), India’s first and only indigenous Hepatitis A vaccine.

In addition an award for being the Best in Veterinary Healthcare Vaccines was also given at the Hybiz Tv Business Excellence Awards Function held at the HICC Novotel in Hyderabad. This reaffirms IIL’s leadership across both human and animal health segments.

The evening celebrated organizations that lead, innovate and set new benchmarks for the industry, along with visionaries who have shaped healthcare in India. Gracing the occasion as Guest of Honour, Dr. K. Anand Kumar, Managing Director, IIL, highlighted the organization’s unwavering commitment to public health, indigenous vaccine development, and affordable access to life-saving immunization. Dr. Kumar emphasized that innovations like Havisure reflect IIL’s broader mission of contributing to India’s self-reliance in vaccines. He also underscored the crucial role of IIL’s veterinary healthcare segment in safeguarding animal health, supporting farmers’ livelihood strengthening the One Health Initiative .

Representing IIL at the event were Mr. Sarthak Vasudeva, Sr. Vice President – International Business, Mr. Shakul Srivastava, Vice President – Human Health Business, and Mr. Sobhan Babu, Vice President – Animal Health Business.

National Dairy Development Board

22/12/2025

Indian Immunologicals Limited (IIL) with an impressive growth story has catapulted as one among the top league vaccine companies in India.

Availability, Affordability, Accessibility and Adaptability are inherent in the DNA of IIL, making it as a single largest contributor to vaccine self sufficiency of the nation.

Being one of the largest manufacturers of human and animal vaccines, IIL is a company committed to One Health and balances profitability with social good, a unique model in the vaccine industry.

Outlook Publishing (Outlookindia) Pvt Ltd carried an in depth article on Indian Immunologicals Limited and an exclusive interview with Dr K Anand Kumar, MD, IIL, which highlights the significant achievements of IIL and It’s service to the nation. This article was published along side article on National Dairy Development Board and its other subsidiaries.

19/12/2025

Indian Immunologicals Limited (IIL) Honoured for Excellence in Healthcare Innovation!

IIL has been recognized by the Confederation of Indian Industry (CII) at the ‘CII Industrial Innovation Awards 2025 : Top 100 Innovative Company’, chosen from leading sectors, including healthcare, IT, defence, aerospace, power, engineering, automobile, telecom, FMCG and others.

The award was presented during the ‘CII Global Summit on Technology, R&D and Intellectual Property’ in New Delhi held during 16 - 17 December 2025, themed ‘From Dependence to Dominance: Research, Deep Tech, and IP for AtmaNirbhar Bharat’. Dr. Santosh B Ghadage, Sr. Vice President - Mfg. had the privilege of accepting the award on behalf of IIL.

This recognition was conferred to IIL for its development of indigenous healthcare solutions like Havisure, India’s first indigenously developed Hepatitis A vaccine, which addresses critical public health need and reduces the country's reliance on imported vaccines; and for developing the vaccine against Infectious Bovine Rhinotracheitis, India’s first gE-deleted DIVA marker vaccine for this disease, which contributes to improving dairy productivity and enhancing farmer welfare.

The event brought together industry leaders, policymakers, academia, and research institutes, fostering discussions on innovation, R&D, and India’s journey toward self-reliance.

This award is a testament to:

-The visionary leadership of our Managing Director, Dr. K. Anand Kumar, which fosters a culture of scientific rigor and innovation.
-The capabilities of our manufacturing and R&D teams.
-Commitment to national healthcare priorities.

Congratulations to the entire IIL team on this continued recognition of excellence!

National Dairy Development Board

09/12/2025

Telangana Rising Global Summit is organized by the Government of Telangana at the Bharat Future City, Hyderabad, India, from 8th-12th of December 2025. The objective of the summit is to present a roadmap for Telangana state to achieve USD 3 Trillion economy by 2047, in line with Viksit Bharat of the Government of India.

Hon'ble Shri Jishnu Dev Varma, Governor of Telangana, inaugurated this Global event in the presence of Shri A Revanth Reddy, Chief Minister of Telangana, several Indian and global dignitaries such as Shri Kailash Satyarthi Nobel Laureate, G Kishan Reddy, Hon'ble Union Minister, Shri Bhatti Vikramarka Dy CM, Shri D Sridhar Babu, Hon'ble Minister IT, EC, I&C Telangana. Eric Swider, Trump Media CEO. Karan Adani, Adani Group etc. were present.

This event showcased each and every sector which can together propel Telangana to a USD 3 Trillion economy by 2047. Technology and Life Sciences sectors are some of the key sectors in shaping the success of Telangana.

Speaking on the occasion during a panel session related to Life Sciences sector, Dr K Anand Kumar, Managing Director, Indian Immunologicals said, “Value of a product should not be seen purely from a money perspective but the impact it creates by use. He added that technologies such as mRNA and Artificial Intelligence, intranasal vaccines, micro-array patches, thermostable vaccines are the areas which IIL is working on. He also emphasised the importance of One Health and IIL’s inherent strength as a leading player and Champion in One Health. He stated that IIL is the single largest contributor to the nation achieving vaccine self-sufficiency.“

Other dignitaries in the panel, such as Shri D Sridhar Babu, Minister of IT, Government of Telangana, Dr Madan Mohan Reddy, Director Aurobindo Pharma, Dr Satyanarayana Chava, Chairman and CEO, Laurus Labs, Dr Srinivas Oruganti, Director Dr Reddy's Labs, Ms Priyanka Chigurupati, Granules India, contributed to the panel discussion.

National Dairy Development Board

08/12/2025

Dr. K. Anand Kumar, Managing Director of Indian Immunologicals Limited (IIL), and Dr. Santosh Balasaheb Ghadage, Sr. VP - Mfg. visited the ICAR–National Institute of Foot and Mouth Disease (ICFMD/ICAR-NIFMD), Bhubaneswar, for an insightful interaction with Director Dr. R.P. Singh, Dr. Jajati Mohapatra, Principal Scientist, along with senior scientists. The discussions focused on strengthening India’s animal health landscape through advanced technologies, newer diagnostics, and improved/next-generation vaccine approaches.

The visit began with presentations from both organizations, during which Dr. Anand Kumar highlighted IIL’s four-decade legacy in supplying essential animal vaccines and its expansion into the human vaccine space, contributing significantly to India’s vaccine self-sufficiency. Dr. R.P. Singh, Director, ICFMD along with senior scientists then discussed on the institute’s wide-ranging work, including high-containment FMD research, molecular diagnostics, national-level training programs, development of modern vaccine platforms, testing of trade and regulatory samples, and simplified quality-control systems aimed at improving veterinary biologicals and animal health.

During the facility tour, Dr. Anand Kumar and Dr. Santosh Ghadage visited high-biocontainment research laboratories, FMDV characterization units, molecular epidemiology sections, diagnostic development facilities, and QC innovation laboratories. The IIL team expressed deep appreciation for the scientific rigor, commitment, and national relevance of the work being carried out at the institute.

The interaction also covered potential areas of collaboration, particularly in enhancing diagnostic capabilities and exploring the use of AI and machine learning for improved FMD vaccine strain matching. Both institutions recognized the value of combining ICFMD’s research strengths with IIL’s proven manufacturing expertise to accelerate the development of affordable, high-quality vaccines and diagnostic tools for India’s livestock sector.

The visit concluded with a shared understanding that stronger partnerships, supported by advanced research and digital technologies, will play a pivotal role in safeguarding the country’s livestock health and improving disease preparedness.

National Dairy Development Board